Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France
European Journal of Clinical Pharmacology · 2023-02 · 79 (2) · 229-236
DOI: 10.1007/s00228-022-03422-y ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 12.12.2022. Verfasst von D Adopo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Universite Victor Segalen, Bordeaux, France. Hauptthemen laut MEDLINE: Physicians, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Because patients and patient organizations want to strengthen their role in the care pathway and drug evaluation and in order to improve pharmacovigilance activities, European competent authorities implemented regulations to allow direct reporting of adverse drug reactions related to medicinal products by patients in 2012.
Objectives
To describe evolution and analyze determinants of patient reporting activity in France in order to assess patient involvement in pharmacovigilance.
Method
Using the French national pharmacovigilance database, univariate and multivariate analyses were performed to compare the characteristics of adverse drug reaction (ADR) reports from patients and healthcare professionals (HCP) between 2011 and 2020. The relationship between regional patient ADR report activity and regional care provision and socio-professional characteristics was analyzed using the principal component analysis.
Results
A significant and higher increase in ADR reports over time from patients ( r = 0.89, p < 0.001) compared to HCP ( r = 0.27, p = 0.002) has been observed. Patient ADR report activities compared to HCP concerned more women (80% vs. 55%, p < 0.001), younger age classes ( p < 0.001), reporting through web portal (83% vs. 17%, p < 0.001), and less serious events (26% vs. 63%, p < 0.001). In the principal component analysis, regional patient reporting activity was related to socio-professional categories, age classes, and densities of hospital beds and physicians.
Conclusion
Our results confirm an increasing involvement of patients in ADR report activities. The determinants of patient reporting activities are not only related to drug and medical factors but also to social factors. Digital tools may also play a role in health democracy in pharmacovigilance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Universite Victor Segalen, Bordeaux, France.
- Agence Nationale de Sécurité du Médicament, Saint-Denis, 93200, France.
- Pharmacology & Pharmacovigilance Department, Regional Pharmacovigilance Centre of Tours, Tours, France.
- Pharmacology & Pharmacovigilance Department, Regional Pharmacovigilance Centre of Rennes, Rennes, France.
- Pharmacology & Pharmacovigilance Department, Regional Pharmacovigilance Centre Marseille Provence Corse, Marseille, France.
- Agence Nationale de Sécurité du Médicament, Saint-Denis, 93200, France. patrick.maison@ansm.sante.fr.
Zitieren
APA
Adopo, D., Daynes, P., Benkebil, M., Debs, A., Jonville-Berra, A. P., Polard, E., Micallef, J., & Maison, P. (2023). Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France. European Journal of Clinical Pharmacology, 79(2), 229-236. https://doi.org/10.1007/s00228-022-03422-y
Vancouver
Adopo D, Daynes P, Benkebil M, Debs A, Jonville-Berra AP, Polard E, et al. Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France. European Journal of Clinical Pharmacology. 2023;79(2):229-236. doi:10.1007/s00228-022-03422-y
BibTeX
@article{Adopo2023,
author = {Adopo, D and Daynes, P and Benkebil, M and Debs, A and Jonville-Berra, A P and Polard, E and Micallef, J and Maison, P},
title = {Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France},
journal = {European Journal of Clinical Pharmacology},
year = {2023},
volume = {79},
number = {2},
pages = {229--236},
doi = {10.1007/s00228-022-03422-y}
}
EUVIMED